MedPath

Comparative study of HYLO DUAL INTENSE® and THEALOZ® on the signs and symptoms of dry eyes in patients with keratitis or keratoconjunctivitis

Phase 3
Conditions
keratitis,keratoconjunctivitis, dry eyes
Registration Number
DRKS00030214
Lead Sponsor
aboratoires URSAPHARM SAS
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
80
Inclusion Criteria

Patients who have used artificial tears in the past for few months and, despite this treatment, have symptoms of keratoconjunctivitis and corneal or conjunctival lesions visible through staining.
- The following two conditions must be met on the same eye:
a) Total ocular surface staining score between = 4 and = 9 on the 15-point Oxford scale (including objective diagnosis of keratoconjunctivitis sicca by staining)
b) At least one of the following objective signs:
Decreased tear volume: Schirmer test without anesthesia between = 3 mm and = 9 mm / 5 min
or:
the sum of 3 tear film break-up time (TBUT) measurements = 30 seconds.
-The patient agrees not to wear contact lenses during the study
- Dry eye symptoms with at least 3 out of 6 symptoms (frequency = 1 and intensity = 2) (ICO index) with symptoms of moderate to severe intensity
-The patient is willing and able to comply with study protocol requirements
-The patient is affiliated to the social security system
- Patient's informed consent form, dated and signed

Exclusion Criteria

- Inability to understand the language and/or content of the study for which the informed consent is being obtained
- Corneal disease unrelated to dry eyes
- Application of artificial tears less than 4 hours before the ophthalmological examinations that will be performed during the admission visit
- Prior participation in this study
- Concurrent participation in a clinical study, or another clinical study within 4 weeks before and after entering the study
- Best corrected visual acuity < 1/10
- Severe blepharitis
- Severe dry eye with any of the following
a) Anomalies of the eyelids
b) Ocular surface metaplasia
c) Filamentous keratitis
d) Corneal neovascularization
- History of eye trauma, eye infection or eye inflammation less than 3 months
- History of allergic ocular pathologies or ocular herpes of less than 3 months
- Acute infectious or viral eye diseases
- History of inflammatory corneal ulcer, recurrent erosion or uveitis
- Cataract surgery, laser in situ keratomileusis, photorefractive keratectomy, and other limbal or corneal incision surgeries within the last 12 months
- Any ocular surface abnormality not related to dry eye
- Intolerance, hypersensitivity, known allergy to one of the components of the two products: HYLO DUAL INTENSE® or THEALOSE®
- Patient with hypersensitivity to fluorescein
- Women of childbearing potential not using an effective method of contraception (oestrogen-progestin, IUD) must have a pregnancy test and the result must be available prior to the study's fluorescein instillation
- Any conditions that may prevent safe participation and interfere with protocol requirements (e.g. alcohol, illegal substances)
- Wearing of contact lenses for the duration of the study
- All protected persons

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Comparison of the development of the mean values of the total score of the staining of the ocular surface (15-point Oxford scale) from day 35 and day 0 between HYLO DUAL INTENSE® and THEALOSE®. The eye most affected on day 0 is evaluated.
Secondary Outcome Measures
NameTimeMethod
- Analysis of the mean variations obtained in the total ocular surface staining score on the 15-point Oxford scale at D84 of the most affected eye.<br>- Corneal staining score on the 5-point Oxford scale at D35 and D84 of the most affected eye.<br>- Evaluation of the nasal and temporal conjunctival staining according to the 5-point Oxford scale at D35 and at D84 of the most affected eye.<br>- Frequency and intensity of the following symptoms related to dry eye on D35 and D84 (ICO index): dry eye, foreign body, tingling, fatigue, pain, itching<br>-adverse events
© Copyright 2025. All Rights Reserved by MedPath